Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Prostate

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) based on conventional imaging, as compared to placebo plus ADT.
Prostate
III
Moses, Kelvin
NCT03767244
VICCURO19125

Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer

Kidney (Renal Cell)

This clinical trial evaluates which methods of blood transfusion are best for patients undergoing kidney surgery. Allogenic (donor) blood transfusion has been shown to cause more side effects (with the lungs, immune system, and circulation, for example) as well as worse cancer outcomes. These concerns have encouraged methods to decrease allogenic blood transfusion. Blood transfusion is defined as a medical treatment that replaces blood that is lost during surgery and is causing changes in blood pressure or heart rate due to that loss. There are two sources of blood for transfusion, allogenic and autologous. Allogenic blood is blood that is provided from healthy blood donors. Autologous blood is provided from the patient for their own use. Techniques that can reduce the need for allogenic blood transfusion include acute normovolemic hemodilution and cell salvage, which use the patient's own blood (autologous) in transfusion. This study aims to reduce the number of units of allogenic (donated) blood that is transfused.
Kidney (Renal Cell)
N/A
Moses, Kelvin
NCT04922307
VICCURO2114

Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing

Prostate

This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
Prostate
N/A
Moses, Kelvin
NCT04404894
VICCURO2089

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

Prostate

The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his / her physician would have already made the decision to treat patient with darolutamide per local standard practice.
Prostate
N/A
Moses, Kelvin
NCT04122976
VICCURO2101

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: